Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?

Yoav Golan

Research output: Contribution to journalComment/debate

5 Scopus citations

Abstract

Prior analyses suggest that empiric fluconazole for ICU patients with sepsis is cost-effective. Using updated estimates of efficacy and cost, Zilberberg and colleagues compare the use of micafungin with that of fluconazole. The authors conclude that micafungin is an attractive alternative to fluconazole. This conclusion is driven by recent reduction in micafungin's cost and by better activity of micafungin against azole-resistant Candida species. Their results are limited by inflated estimates of efficacy, life expectancy and risk of Candida sepsis. This commentary explores the rationale for early anti-Candida strategies in the ICU and highlights the contribution and limitations of the article by Zilberberg and colleagues.

Original languageEnglish
Pages (from-to)180
Number of pages1
JournalCritical Care
Volume13
Issue number4
DOIs
StatePublished - 1 Jan 2009
Externally publishedYes

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Fingerprint

Dive into the research topics of 'Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?'. Together they form a unique fingerprint.

Cite this